TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04285658

Intervention type: PROCEDURE
Intervention: Ureteroscopy
Description: An outpatient endoscopic surgery that accesses the ureters and kidneys per the urethra to fragment and remove the stones. Many patients who undergo ureteroscopy (URS), Shockwave lithotripsy (SWL), or percutaneous nephrolithotomy (PCNL) also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).

Intervention type: PROCEDURE
Intervention: Percutaneous Nephrolithotomy
Description: A minimally invasive surgery in which a \~1cm flank incision is made, and a scope is passed through a tubular sheath into the kidney to fragment and remove the stone. There is typically a 1- to 2-day hospital stay. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).

Intervention type: PROCEDURE
Intervention: Shock Wave Lithotripsy
Description: A non-invasive outpatient procedure that targets stones in the kidney or ureter with x-ray or ultrasound and uses shockwaves generated outside the body to fragment them; the fragments pass down the ureter and the patient expels them in the urine. Many patients who undergo URS, SWL, or PCNL also have temporary tubes placed after the surgery to facilitate drainage, either internally (a stent) or externally (a nephrostomy tube).
Study: NCT03091686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA SB Intervention Slideshow
Description: In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAPA MVPA Attention-Control Slideshow
Description: In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
Study: NCT02104492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a 12-week Respiratory Muscles Training Program (RMTP)
Description: Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
Study: NCT00845884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
Description: * Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~* Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~* Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days.
Study: NCT03253484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NAFL-treatment
Description: non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
Study: NCT02914925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSpring/CIT
Description: Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
Study: NCT02768454

Intervention type: DRUG
Intervention: medical review of controlled broad-spectrum antibiotics
Description: medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
Study: NCT00603577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaliproden
Description: 1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
Study: NCT04603976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Study: NCT03179644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of oesophageal pressure and pleural pressure
Description: Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
Study: NCT04234113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp alfa
Description: A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
Study: NCT04245085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit.
Study: NCT01382433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetoencephalograph (MEG)
Description: Brain imaging device that records the magnetic fields in the brain.
Study: NCT00730730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Iliac Stent
Description: Iliac stenting
Study: NCT04245085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
Study: NCT01382433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cambridge Neuropsychological Test Automated Battery (CANTAB).
Description: the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cambridge Neuropsychological Test Automated Battery (CANTAB).
Description: the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
Study: NCT04245085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
Study: NCT01382433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)
Description: The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)
Description: The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
Study: NCT03175237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Study: NCT04310410

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combined radiotherapy and MR-HIFU
Description: Following standard EBRT (single or multiple fraction), patients will receive one MR-HIFU treatment with the Profound Sonalleve MR-HIFU device on the most painful of their bone metastases. This treatment will take place in a short time frame of 3 hours to maximum 4 days. Patients will be followed up until 4 weeks after treatment. During follow-up they will be phoned around day 3, 7, 14, 21 and 28 to retrieve pain scores, pain medication and (serious) adverse events. At day 3 the patient's experience with the combined treatment will also be inquired.
Study: NCT04388891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally supervised therapy with the ReHapticKnob
Description: The therapy with the ReHapticKnob is performed in the clinic in addition to the conventional therapy. During the supervised and semi-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes. During the minimally supervised phase (third and fourth week), the duration of the ReHapticKnob therapy is not specified, since the patient can decide by him/herself when to use the device, e.g. during freetime or during the weekend.
Study: NCT01183000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the peritoneum at cs
Description: Injection of 5 mg Marcaine (anesthetic solution) to the leg
Study: NCT02890823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study: NCT00405977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
Study: NCT04245085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
Study: NCT03269110

Intervention type: DIAGNOSTIC_TEST
Intervention: SRS 2, CBCL, BRIEF-P
Description: This study does not involve an intervention.
Study: NCT03083210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
Study: NCT03982433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Cognitive Behavioral Management for Alcohol and Pain
Description: Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
Study: NCT00673361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent decrescendo biochemotherapy regimen
Description: * Temozolomide: 200mg/m\^2, daily, PO, days 1-4~* Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4~* Cisplatin: 20mg/m\^2, daily IV, days 1-4~* IL (interleukin)-2: - 18 milli-International unit (MIU)/m\^2, IVCI (intravenous continual infusion), day 1~* 9 MIU/m\^2, IVCI, day 2~* 4.5 MIU/m\^2, IVCI, days 3 \& 4~* Interferon (IFN) alpha: 5 MIU/m\^2, daily, SC (subcutaneously), days 1-5~* 5-day inpatient regimen, to be repeated every 21 days
Study: NCT00730730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Complete SE Iliac Stent
Description: Self-expanding stent
Study: NCT00673361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Temozolomide plus Sorafenib
Description: Temozolomide: 75mg/m\^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
Study: NCT01982383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Study: NCT02801058

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative techniques on thoracic diaphragm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative techniques on thoracic diaphragm
Study: NCT00650156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg single sc dose
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 MK-0517 (PS80) + 2 mg midazolam
Description: MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 115 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study: NCT04414969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide
Description: Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
Study: NCT02809079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 500mg Bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 10mg Qd
Study: NCT03453099

Intervention type: OTHER
Intervention: Preoperative Questionnaires
Description: The participants will be asked to complete 5 questionnaires:~1. An abbreviated version of the Caffeine Assessment Tool (CAT)~2. Sleep Questionnaire (SQ)~3. Surgical Fear Questionnaire (SFQ)~4. WHO Alcohol AUDIT Tool~5. WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness

Intervention type: OTHER
Intervention: Postoperative Subjective Pain Scores
Description: After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.